Dataset Viewer
Auto-converted to Parquet Duplicate
chunk_id
large_string
cik
large_string
ticker
large_string
company_name
large_string
sic_code
large_string
accession
large_string
form_type
large_string
filed_at
large_string
fiscal_year
float64
fiscal_period
large_string
chunk_type
large_string
heading
large_string
pre_context
large_string
text
large_string
source_url
large_string
facts_count
int32
scale_cue_in_text
bool
sample_stratum
large_string
facts
list
non_target_spans
list
0204bc6c5ba31867024d8a53831d078c06915b6de3e5b4504dc99a90a1bbae1f
0001516551
SKYE
Skye Bioscience, Inc.
2834
000151655122000022
10-Q
2022-08-15
2,022
Q2
notes
Loss Per Common Share
0.01 ) The following outstanding shares of common stock equivalents were excluded from the computation of diluted loss per share of common stock for the periods presented because including them would have been anti-dilutive:
| | Three Months Ended June 30, (Unaudited) | Six Months Ended June 30, (Unaudited) | | 2022 | 2021 | 2022 | 2021 | Stock options | 37,755,000 | 21,850,000 | 37,755,000 | 21,850,000 | Common shares underlying convertible debt | 5,570,932 | 5,213,498 | 5,570,932 | 5,213,498 | Warrants | 136,187,225 | 50,213,334 | 136,18...
https://www.sec.gov/Archives/edgar/data/1516551/000151655122000022/skye-20220630.htm
16
true
10-Q|notes|16-40
[ { "fact_id": "3eb51fd98246294e9678719d5b9450b872961b52122bc160f214bbf7e1daff14", "concept": "us-gaap#AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unit": "shares", "period": "duration:2022-04-01..2022-06-30", "value": "37755000", "displayed_text": "37,755,000", ...
[ { "span_text": "30,", "start": 28, "end": 31, "class": "date" }, { "span_text": "30,", "start": 68, "end": 71, "class": "date" }, { "span_text": "2022", "start": 88, "end": 92, "class": "year" }, { "span_text": "2021", "start": 95, "end": 99, ...
32d15ef96fad7b6065e7317cc67151eb727c35484b5f65d143d9d8319c628e80
0001516551
SKYE
Skye Bioscience, Inc.
2834
000151655122000022
10-Q
2022-08-15
2,022
Q2
mda
General Trends and Outlook
drome, macular degeneration and diabetic retinopathy. Data we presented at the American Association of Pharmaceutical Scientists ("AAPS") meeting held in November 2017 revealed that an early ocular formulation of SBI-200 was able to penetrate multiple compartments of the eye, including reaching the retina and the optic...
The evolving COVID-19 pandemic has prompted governments and businesses to take unprecedented measures, such as restrictions on travel and business operations, temporary closures of business, quarantines, and shelter-in-place orders. The COVID-19 pandemic has significantly curtailed global economic activity and caused s...
https://www.sec.gov/Archives/edgar/data/1516551/000151655122000022/skye-20220630.htm
0
false
abstention|0
[]
[ { "span_text": "19", "start": 19, "end": 21, "class": "untagged_amount" }, { "span_text": "19", "start": 243, "end": 245, "class": "untagged_amount" }, { "span_text": "19", "start": 396, "end": 398, "class": "untagged_amount" }, { "span_text": "1", ...
35c7c6ae4641d006b65e9ffb23be620c7ac396168cb84e155e06d1681bdda369
0001516551
SKYE
Skye Bioscience, Inc.
2834
000151655122000022
10-Q
2022-08-15
2,022
Q2
notes
Fair Value Measurements
es The Company’s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company’s product candidates, uncertainties related to the impact of COVID-19 (Note 1), risks related to operating pri...
Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the “exit price”) in the principal or most advantageous market for the asset or liability in an orderly transaction between market partici...
https://www.sec.gov/Archives/edgar/data/1516551/000151655122000022/skye-20220630.htm
0
false
abstention|0
[]
[ { "span_text": "1", "start": 671, "end": 672, "class": "note_ref" }, { "span_text": "2", "start": 859, "end": 860, "class": "note_ref" }, { "span_text": "1", "start": 898, "end": 899, "class": "note_ref" }, { "span_text": "3", "start": 1174, "e...
3f59d94778eea08a0272be2c1ba3e1c52c47b10f7062697254e9ea6ce266af61
0001516551
SKYE
Skye Bioscience, Inc.
2834
000151655122000022
10-Q
2022-08-15
2,022
Q2
notes
Liquidity and Going Concern
suffer in the event of continued business interruptions, supply chain issues, delayed clinical trials, production or a lack of laboratory resources due to the pandemic and other global conditions. It is possible that the Company may encounter other similar issues relating COVID-19 or the cyberattack that will need to ...
The Company has made adjustments to its operations designed to keep its employees safe and comply with federal, state and local guidelines. The extent to which COVID-19 may further impact the Company’s business, results of operations, financial condition and cash flows will depend on future developments, which are high...
https://www.sec.gov/Archives/edgar/data/1516551/000151655122000022/skye-20220630.htm
0
false
abstention|0
[]
[ { "span_text": "19", "start": 166, "end": 168, "class": "date" }, { "span_text": "19,", "start": 395, "end": 398, "class": "untagged_amount" }, { "span_text": "100", "start": 683, "end": 686, "class": "untagged_amount" }, { "span_text": "19", "star...
688c003fac069c4fe55c2884ce1173fd6473083aca4ad629ca122ed9ce8274d9
0001516551
SKYE
Skye Bioscience, Inc.
2834
000151655122000022
10-Q
2022-08-15
2,022
Q2
notes
Stock-Based Compensation Expense
ment activities, other expenses and equipment and laboratory supplies. Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not ...
Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the fair value is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. Upon the exercise of stock option awards, the Company's policy is to issue new shares of its com...
https://www.sec.gov/Archives/edgar/data/1516551/000151655122000022/skye-20220630.htm
0
false
abstention|0
[]
[ { "span_text": "718", "start": 1248, "end": 1251, "class": "note_ref" }, { "span_text": "718", "start": 1294, "end": 1297, "class": "note_ref" } ]
8ada7c5418e0872976da5ea40bc4dc776029c978579ee7c4f6367f6295b601f3
0001516551
SKYE
Skye Bioscience, Inc.
2834
000151655122000022
10-Q
2022-08-15
2,022
Q2
notes
Asset Acquisition
— 4,000,000 — Asset Acquisition
The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in ...
https://www.sec.gov/Archives/edgar/data/1516551/000151655122000022/skye-20220630.htm
0
false
abstention|0
[]
[]
0342ef757ebaf32b996f6dd646ead2b83f99eac55d6b7cde7a09fb502a150711
0000318833
TISI
TEAM, INC.
7600
000031883323000018
10-Q
2023-05-11
2,023
Q1
table_context
(in thousands, except share and per share data) (part 2)
1 Table of Contents PART I—FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS TEAM, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data)
| | March 31, 2023 | December 31, 2022 | ASSETS | (unaudited) | Current assets: | Cash and cash equivalents | $ | 31,869 | $ | 58,075 | Accounts receivable, net of allowance of $ 4,926 and $ 5,262 respectively | 178,211 | 186,689 | Inventory | 37,998 | 36,331 | Income tax receivable | 828 | 779 | Prepaid expenses and o...
https://www.sec.gov/Archives/edgar/data/0000318833/000031883323000018/tisi-20230331.htm
74
true
10-Q|table_context|41+
[ { "fact_id": "a047f54206c375a9d476c65a0af937de582b582dfc8f55297db8ea0fabfbf9fa", "concept": "us-gaap#CashAndCashEquivalentsAtCarryingValue", "unit": "monetary:USD", "period": "instant:2023-03-31", "value": "31869000", "displayed_text": "31,869", "text_start": 114, "text_end": 120, ...
[ { "span_text": "31,", "start": 10, "end": 13, "class": "date" }, { "span_text": "2023", "start": 14, "end": 18, "class": "year" }, { "span_text": "31,", "start": 30, "end": 33, "class": "date" }, { "span_text": "2022", "start": 34, "end": 38, ...
0006f990a30c707617596836a4cde3f05c235bd062e31a37d4b47f07fce2161a
0000894627
EGY
VAALCO Energy, Inc.
1311
000143774923030706
10-Q
2023-11-08
2,023
Q3
table_context
null
$ 120 $ 121,612 11 Table of Contents
(in thousands) |   | Gabon |   |   | Egypt |   |   | Canada |   |   | Equatorial Guinea |   |   | Corporate and Other |   |   | Total |   | Long-lived assets from continuing operations: |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | As of September 30, 2023 |   | $ | 1...
https://www.sec.gov/Archives/edgar/data/894627/000143774923030706/0001437749-23-030706-index.htm
12
true
10-Q|table_context|6-15
[ { "fact_id": "9e3bd0fcf030c8248de40787d68715483bc333ef5ddf9ca7aaefbf92752266e5", "concept": "us-gaap#NoncurrentAssets", "unit": "monetary:USD", "period": "instant:2023-09-30", "value": "186966000", "displayed_text": "186,966", "text_start": 319, "text_end": 326, "dimensions": [ ...
[ { "span_text": "30,", "start": 300, "end": 303, "class": "date" }, { "span_text": "2023", "start": 304, "end": 308, "class": "year" }, { "span_text": "31,", "start": 453, "end": 456, "class": "date" }, { "span_text": "2022", "start": 457, "end"...
03be970c222e5c60e03ed31020983ebdc0bb95aaa9740733b1e27152dd725903
0001037540
BXP
BOSTON PROPERTIES, INC.
6798
000165642320000007
10-K
2020-03-02
2,019
FY
notes
16. Stock Option and Incentive Plan
2.68 % , 2.63 % and 2.14 % and an expected price volatility of 27.0 % , 27.0 % and 28.0 % , respectively.
There were no non-qualified stock options granted during the years ended December 31, 2019 , 2018 and 2017 . A summary of the status of Boston Properties, Inc.’s stock options as of December 31, 2019 , 2018 and 2017 and changes during the years then ended are presented below: | Shares | Weighted-Average Exercise Price ...
https://www.sec.gov/Archives/edgar/data/1037540/000165642320000007/bxpandbplp201910-k.htm
15
false
10-K|notes|6-15
[ { "fact_id": "631bdb359ae290e18c4c7faf86e59937e4d4cb73a47938f2564a48281ce3386d", "concept": "ext-0001037540#NonQualifiedStockOptionsIssued", "unit": "shares", "period": "instant:2019-12-31", "value": "0", "displayed_text": "no", "text_start": 11, "text_end": 13, "dimensions": [],...
[ { "span_text": "31,", "start": 82, "end": 85, "class": "date" }, { "span_text": "2019", "start": 86, "end": 90, "class": "year" }, { "span_text": "2018", "start": 93, "end": 97, "class": "year" }, { "span_text": "2017", "start": 102, "end": 106...
000a334a4124ccdc983d3a3b71f9c32d69b6bf516742e2582f164fa567d9d3f5
0000912593
SUI
SUN COMMUNITIES, INC
6798
000091259321000185
10-Q
2021-07-27
2,021
Q2
table_context
(Unaudited)
three reportable segments are: (i) Manufactured home ("MH") communities, (ii) Recreational vehicle ("RV") resorts and (iii) Marinas. 7 SUN COMMUNITIES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued) (Unaudited) 2. Revenue The following tables detail our revenue by major source (in thousands):
| | Three Months Ended | | June 30, 2021 | June 30, 2020 (1) | MH | RV | Marina | Consolidated | MH | RV | Marina | Consolidated | Revenues | Real property | $ | 199,948 | $ | 132,463 | $ | 73,494 | $ | 405,905 | $ | 181,713 | $ | 69,414 | N/A | $ | 251,127 | Home sales | 69,922 | 11,926 | — | 81,848 | 35,074 | 3,456 |...
https://www.sec.gov/Archives/edgar/data/912593/000091259321000185/sui-20210630.htm
42
true
10-Q|table_context|41+
[ { "fact_id": "fa6e924b9fa6ead4393985ee1a3b48f4c75aa78604df41b712fafe0d8be4c01b", "concept": "us-gaap#RevenueFromContractWithCustomerIncludingAssessedTax", "unit": "monetary:USD", "period": "duration:2021-04-01..2021-06-30", "value": "199948000", "displayed_text": "199,948", "text_start":...
[ { "span_text": "30,", "start": 32, "end": 35, "class": "date" }, { "span_text": "2021", "start": 36, "end": 40, "class": "year" }, { "span_text": "30,", "start": 48, "end": 51, "class": "date" }, { "span_text": "2020", "start": 52, "end": 56, ...
01c3b32aae1572a6376c0efb52643a5b1e6f7787bb485dbb16bee1edea25ac94
0001646972
ACI
Albertsons Companies, Inc.
5411
000164697219000054
10-Q
2019-07-24
2,019
Q1
notes
Significant Accounting Policies
or omitted for the interim periods presented in accordance with accounting principles generally accepted in the United States of America ("GAAP"). In the opinion of management, the interim data includes all adjustments, consisting of normal recurring adjustments, necessary for a fair statement of the results for the i...
Restricted cash: Restricted cash is included in Other current assets or Other assets depending on the remaining term of the restriction and primarily relates to funds held in escrow. The Company had $ 51.6 million and $ 41.6 million of restricted cash as of June 15, 2019 and February 23, 2019 , respectively. Inventorie...
https://www.sec.gov/Archives/edgar/data/1646972/000164697219000054/aciq1-1910xq.htm
5
false
10-Q|notes|2-5
[ { "fact_id": "aca671ed3283e29ffcb40b76f8cfe8f41babf9bd91e852706e2d1824a48eb893", "concept": "us-gaap#RestrictedCash", "unit": "monetary:USD", "period": "instant:2019-06-15", "value": "51600000", "displayed_text": "51.6", "text_start": 201, "text_end": 205, "dimensions": [], "...
[ { "span_text": "15,", "start": 263, "end": 266, "class": "date" }, { "span_text": "2019", "start": 267, "end": 271, "class": "year" }, { "span_text": "23,", "start": 285, "end": 288, "class": "date" }, { "span_text": "2019", "start": 289, "end"...
001ac321bf1bd1277c042710397044521f0653f5ba6e5e308165678257e54844
0001295810
SHO
Sunstone Hotel Investors, Inc.
7011
000110465926055508
10-Q
2026-05-05
2,026
Q1
table_context
null
Table of Contents SUNSTONE HOTEL INVESTORS, INC. UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) Supplemental Disclosure of Cash Flow Information March 31, 2026 2025 Cash and cash equivalents $ 91,134 $ 72,334 Restricted cash 75,549 76,460 Total cash and cash equivalents and restricted cash shown on the ...
| Three Months Ended March 31, | 2026 | 2025 Cash paid for interest, net of capitalized interest | $ | 15,150 | $ | 13,004 Cash paid (refunded) for income taxes, net | $ | 70 | $ | ( 145 ) Changes in operating lease right-of-use assets | $ | 320 | $ | 1,203 Changes in operating lease obligations | ( 537 ) | ( 1,344 ) C...
https://www.sec.gov/Archives/edgar/data/0001295810/000110465926055508/sho-20260331x10q.htm
10
true
10-Q|table_context|6-15
[ { "fact_id": "a7abf848f167695698f307823ed1f741be89018ad06eda173222d1c1a577bbcd", "concept": "us-gaap#InterestPaidNet", "unit": "monetary:USD", "period": "duration:2026-01-01..2026-03-31", "value": "15150000", "displayed_text": "15,150", "text_start": 103, "text_end": 109, "dimens...
[ { "span_text": "31,", "start": 27, "end": 30, "class": "date" }, { "span_text": "2026", "start": 33, "end": 37, "class": "year" }, { "span_text": "2025", "start": 40, "end": 44, "class": "year" } ]
000b05069e23cf0959ece65864c5d3f954e763fe7c5fddc008b1258044689723
0001032208
SRE
SEMPRA ENERGY
4932
000008652118000091
10-Q
2018-11-07
2,018
Q3
table_context
Sempra Energy
74 LONG-TERM DEBT Sempra Energy On January 12, 2018, we issued the following debt securities and received net proceeds of $ 4.9 billion (after deducting discounts and debt issuance costs of $ 68 million ):
| NOTES ISSUED IN LONG-TERM DEBT OFFERING (Dollars in millions) Title of each class of securities | Aggregate principal amount | Maturity | Interest payments Floating Rate (1) Notes due 2019 | $ | 500 | July 15, 2019 | Quarterly Floating Rate (2) Notes due 2021 | 700 | January 15, 2021 | Quarterly 2.400% Senior Notes d...
https://www.sec.gov/Archives/edgar/data/1032208/000008652118000091/0000086521-18-000091-index.htm
7
true
10-Q|table_context|6-15
[ { "fact_id": "8b9213ab3602439655a56195021f31c87fcc9e7d5a8a36ddf766a4e130a501f6", "concept": "us-gaap#DebtInstrumentFaceAmount", "unit": "monetary:USD", "period": "instant:2018-01-12", "value": "500000000", "displayed_text": "500", "text_start": 197, "text_end": 200, "dimensions":...
[ { "span_text": "(1)", "start": 172, "end": 175, "class": "other" }, { "span_text": "2019", "start": 186, "end": 190, "class": "year" }, { "span_text": "15,", "start": 208, "end": 211, "class": "date" }, { "span_text": "2019", "start": 212, "end...
090432c6604a8e91712f65765aa2da08d499edd418b14821c09f1592a508375a
0001596812
ENLV
Enlivex Therapeutics Ltd.
2834
000121390023028398
20-F
2023-04-10
2,022
FY
table_context
Research and development expenses – net
NOTE 16 – SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION a. Research and development expenses – net
Year ended December 31, | (in thousands ) | 2022 | 2021 | 2020 | Payroll and related expenses | $ | 6,371 | $ | 5,054 | $ | 3,183 | Research and development services | | 8,264 | | 4,557 | | 2,438 | Materials | | 2,044 | | 1,505 | | 612 | Share Based Compensation | | 876 | | 1,210 | | 401 | Depreciation | | 740 | | 546 ...
https://www.sec.gov/Archives/edgar/data/1596812/000121390023028398/0001213900-23-028398-index.htm
27
true
20-F|table_context|16-40
[ { "fact_id": "13fb38cc775ab5160100e7233188ec635e746412d33922385cb825faefeb9272", "concept": "us-gaap#AccruedPayrollTaxesCurrent", "unit": "monetary:USD", "period": "instant:2022-12-31", "value": "6371000", "displayed_text": "6,371", "text_start": 100, "text_end": 105, "dimensions...
[ { "span_text": "31,", "start": 20, "end": 23, "class": "date" }, { "span_text": "2022", "start": 44, "end": 48, "class": "year" }, { "span_text": "2021", "start": 51, "end": 55, "class": "year" }, { "span_text": "2020", "start": 58, "end": 62, ...
43c3b0b24c2c1abfc7381d3eea374e8505e7d04661ce3174505ea08dff0b46f6
0001302215
HLI
Houlihan Lokey, Inc.
6282
000130221520000074
10-K
2020-05-15
2,020
FY
table_context
null
er the 2016 Incentive Plan by approximately 12.2 million shares. Under the Amendment, the aggregate number of shares of common stock that are available for issuance under awards granted pursuant to the 2016 Incentive Plan is equal to the sum of (i) 8.0 million and (ii) any shares of our Class B common stock that are su...
| • | 6,540,659 shares of our Class A common stock and Class B common stock;
https://www.sec.gov/Archives/edgar/data/1302215/000130221520000074/0001302215-20-000074-index.htm
1
false
10-K|table_context|1
[ { "fact_id": "a47bb0c79b79e06f24cad98a6afaf2b94021075ea987daf432355795abbf81a7", "concept": "ext-0001302215#ShareBasedCompensationArrangementBySharebasedPaymentAwardIncreaseDecreaseToNumberofSharesAuthorized", "unit": "shares", "period": "instant:2017-10-19", "value": "6540659", "displayed_t...
[]
00186790c8733c2217e890362bb3122b5396dae770c419e1f7f3d670cecd91f1
0001464865
ASII
Accredited Solutions, Inc.
2080
000147793222002592
10-K
2022-04-25
2,021
FY
notes
NOTE 10 – JOINT VENTURE
in convertible debt. See Note 5. On November 17, 2021, the Company issued 83,043 shares of common stock to GS Capital, LLC for a conversion of $ 8,745 in convertible debt. See Note 5. On December 13, 2021, the Company issued 224,964 shares of common stock to GS Capital, LLC for a conversion of $ 8,774 in convertible de...
On August 24, 2020, with an effective date of July 1, 2020, the Company entered into a joint venture agreement with Paul Hervey (“Hervey”) for the purpose of cultivating hemp. Hervey is a licensed hemp cultivator in good standing under the laws of North Carolina with approximately 3,700 square feet of greenhouse cultiv...
https://www.sec.gov/Archives/edgar/data/0001464865/000147793222002592/ghmp_10k.htm
8
false
10-K|notes|6-15
[ { "fact_id": "e5b0364f63359a1dc6aee3a839da22648e1e94b42ffea2dc120ba3cd551cec9a", "concept": "us-gaap#ContributionOfProperty", "unit": "monetary:USD", "period": "duration:2020-08-02..2020-08-24", "value": "160000", "displayed_text": "160,000", "text_start": 462, "text_end": 469, "...
[ { "span_text": "24,", "start": 10, "end": 13, "class": "date" }, { "span_text": "2020,", "start": 14, "end": 19, "class": "year" }, { "span_text": "1,", "start": 51, "end": 53, "class": "date" }, { "span_text": "2020,", "start": 54, "end": 59, ...
End of preview. Expand in Data Studio

FiledFact-Passages - passage-complete, span-grounded SEC fact extraction

5,698 SEC filing passages containing 101,899 financial facts - every fact grounded to its exact characters, every other numeric span labeled as a non-target, and every fact linked to the exact number in the original filing.

Each row contains one clean filing passage (financial-statement tables, notes, or MD&A) and every tagged fact displayed in it: concept, normalized full-unit value, period, unit, decoded dimensions, exact character offsets, and an evidence_url that opens the filing at that number. Years, dates, references, prose percentages, and untagged amounts are labeled in non_target_spans.

Open a fact at the exact number in the original SEC filing

from datasets import load_dataset

ds = load_dataset("StockAlloy/filedfact-passages")
row = ds["validation"][0]

for fact in row["facts"]:
    assert row["text"][fact["text_start"]:fact["text_end"]] == fact["displayed_text"]
Count
Passages 5,698
Companies 4,878
Tagged facts 101,899
Non-target numeric spans 50,658

The task

Input: one filing passage, with optional nearby context.

Output: every tagged financial fact displayed in the passage.

A validation example is a goodwill-by-segment table whose pre_context says “In thousands”:

Engineering
|   |   | Specialty
Health Care
|   |   | Information
Technology
|   |   | Total
$ | 11,918 |   |   | $ | 2,398 |   |   | $ | 7,831 |   |   | $ | 22,147 |

Its four facts:

{"concept": "us-gaap#Goodwill", "value": "11918000", "unit": "monetary:USD",
 "period": "instant:2023-04-01", "text_start": 97, "text_end": 103,
 "dimensions": [{"axis": "StatementBusinessSegmentsAxis",
                 "member": "ext-0000700841#EngineeringMember"}]}

{"concept": "us-gaap#Goodwill", "value": "2398000", "unit": "monetary:USD",
 "period": "instant:2023-04-01", "text_start": 118, "text_end": 123,
 "dimensions": [{"axis": "StatementBusinessSegmentsAxis",
                 "member": "ext-0000700841#SpecialtyHealthCareMember"}]}

{"concept": "us-gaap#Goodwill", "value": "7831000", "unit": "monetary:USD",
 "period": "instant:2023-04-01", "text_start": 138, "text_end": 143,
 "dimensions": [{"axis": "StatementBusinessSegmentsAxis",
                 "member": "ext-0000700841#InformationTechnologyMember"}]}

{"concept": "us-gaap#Goodwill", "value": "22147000", "unit": "monetary:USD",
 "period": "instant:2023-04-01", "text_start": 158, "text_end": 164,
 "dimensions": []}

The displayed 11,918 means 11918000 because the scale cue is in the nearby context. The segment cells carry dimensions; the total has an empty dimensions list.

Some passages intentionally contain no target facts (labeled abstention|0 in sample_stratum).

What passage-complete means

Each passage contains:

  • facts - the financial facts to extract (the numbers the filer tagged in the filing).
  • non_target_spans - every other numeric span, including years, dates, references, prose percentages, and untagged amounts.

A visible numeric token is assigned to one of those two groups. Co-located XBRL facts are kept separately when the filer attached multiple concepts, periods, or dimensions to the same displayed number.

Values and evidence

  • displayed_text is exactly what appears in the passage.
  • text_start and text_end are half-open character offsets into text.
  • value is the normalized full-unit value after applying sign, scale, and numeric format.
  • dimensions records business segment, product, geography, investment, or another dimensional scope.
  • evidence_url opens the corresponding number in the filing; source_url points to the SEC document.

XBRL labels are provided as reported by the filer and may reflect errors in the source filing.

Files and schema

Split Passages Companies Facts Typed-dimension facts
Train 4,922 4,113 87,539 4,181
Validation 776 765 14,360 375
Total 5,698 4,878 101,899 4,556

Train and validation are company-disjoint. The default files contain one nested row per passage; the flat/ directory provides equivalent passage, fact, and non-target tables.

Passage fields

Field Description
chunk_id Stable passage ID and flat-table join key
cik, ticker, company_name, sic_code Issuer identity
accession, form_type, filed_at Filing identity
fiscal_year, fiscal_period Filing-level fiscal focus
chunk_type, heading, pre_context Passage location and nearby context
text Clean passage text; table cells are separated with vertical bars
source_url SEC filing URL
facts_count Number of target facts
scale_cue_in_text, sample_stratum Presentation and sampling metadata
facts Nested target-fact records
non_target_spans Nested non-target numeric spans

Fact fields

Field Description
fact_id Stable fact ID
concept Namespace-qualified XBRL concept
period instant:DATE or duration:START..END
value Precision-preserving normalized value
unit Examples: monetary:USD, per_share:USD, shares, pure
displayed_text Exact characters shown in the passage
text_start, text_end Character offsets into text
scale Power-of-ten presentation scale
decimals, format Filing rounding and numeric-format metadata
dimensions Explicit or typed dimensional scope
evidence_url Link to the corresponding filing location

Each non_target_spans record contains span_text, start, end, and class.

Companion model

The companion model's training data includes these passages, so evaluating it on this dataset would be in-sample. Use separate held-out data for evaluation. The extraction prompt, output format, benchmark protocol, and model results are on the model card.

License and access

This sample is licensed under CC BY-NC 4.0. The license applies to StockAlloy's compilation, annotations, alignments, and derived metadata. The original SEC filings remain independently available through EDGAR.

Contact: data@stockalloy.com.

Evidence links are intended for inspection and light programmatic use. Contact StockAlloy before bulk retrieval.

  • Dataset version: v1.2
  • Selection manifest SHA-256: bc0b3e526742567daa5b17deacb533a4419e5cab4375962cdb5a0e0a7ef78a3a
@dataset{stockalloy_filedfact_passages_2026,
  title   = {FiledFact-Passages: Passage-Complete, Span-Grounded SEC Financial Facts},
  author  = {StockAlloy Research},
  year    = {2026},
  url     = {https://huggingface.co/datasets/StockAlloy/filedfact-passages}
}
Downloads last month
61

Models trained or fine-tuned on StockAlloy/filedfact-passages

Space using StockAlloy/filedfact-passages 1